Nubain, Nalbuphine Newswire

Nubain, Nalbuphine Newswire

Comprehensive Real-Time News Feed for Nubain, Nalbuphine (generic).

Results 1 - 14 of 14 in Nubain, Nalbuphine (generic)

  1. Medical management of opioid-induced constipation differs from other forms of conditionRead the original story w/Photo

    Wednesday Oct 17 | PhysOrg Weblog

    Traditional laxatives are recommended as first-line agents to treat patients with a confirmed diagnosis of opioid-induced constipation , according to a new guideline from the American Gastroenterological Association . If an adequate trial of laxatives results in suboptimal symptom control, the guidelines recommend peripherally-acting mu-opioid receptor antagonist drugs, namely naldemedine, naloxegol and methylnatrexone.


  2. Man caught smuggling drugs in jailRead the original story w/Photo

    Friday Sep 28 | Sun-Star

    CEBU. Gilbert Zabate was caught by guards trying to sneak drugs in jail, hiding the contraband in his behind. A 36-YEAR-OLD man was arrested on Thursday afternoon, September 27, after he allegedly tried to smuggle illegal drugs hidden in his anus inside the Cebu City Jail in Barangay Kalunasan.


  3. Nalbuphine Can Relieve Opioid-Induced Urine RetentionRead the original story w/Photo

    Sep 4, 2018 |

    Nalbuphine can relieve opioid-induced urine retention, according to a case report published online Sept. 4 in the Annals of Internal Medicine .


  4. Nalbuphine may help manage opioid-induced urine retentionRead the original story w/Photo

    Sep 4, 2018 | PhysOrg Weblog

    Nalbuphine may help to manage opioid-induced urine retention. Findings from a brief case report are published in Annals of Internal Medicine .


  5. Why Is It More Painful to Be a Woman?Read the original story w/Photo

    Aug 28, 2018 | Psychology Today

    If you have chronic pain , you're not alone. An estimated 25.3 million adults in the U.S. report severe, daily pain, significantly more women than men, while 55 percent of US adults report at least some pain in the past three months.


  6. Drug peddler' caught with P6.5M shabuRead the original story w/Photo

    Aug 20, 2018 | Sun-Star

    BEHIND BARS. Suspected drug pusher Reinhard Moreno is detained at the Abellana Police Station after he was arrested in an buy-bust operation.


  7. P6.4-M shabu seized in Cebu CityRead the original story w/Photo

    Aug 19, 2018 | Sun-Star

    Chief Inspector Maria Theresa Macatangay, chief of the Abellana Police, presents the money and illegal drugs seized from the high value target suspect Reinhard Moreno. A HIGH-VALUE target was arrested by the Abellana Police after he yielded P6.5 million of shabu during a drug bust in Upper Kawayan, Barangay Sambag 2, this morning, August 20. Chief Inspector Maria Theresa Macatangay, chief of the Abellana Police identified the HVT as Reinhard Moreno, 29. "We traced him after we arrested him for using nalbuphine last 2016.


  8. Cohorts of call center agent in city jail drug bust nabbedRead the original story w/Photo

    Jul 24, 2018 | Sun-Star

    THE two alleged cohorts of the call center agent who tried to smuggle ampules of Nalbuphine inside Cebu City Jail were caught on follow-up operations on Tuesday, July 24, in the villages of Kalunasan and Day-as. Guadupe Police Station Chief Eduard Sanchez identified one of April Jay Fano Ajoc's alleged cohort as Rachel Peligrino Vargas, who was arrested on D. Jakosalem St., Day-as at 6:30 p.m. Vargas yielded seven ampules believed to contain Nalbuphine and five small packs believed to be methamphetamine hydrochloride, or shabu.


  9. Trevi Therapeutics Appoints Yann Mazabraud as Chief Commercial Officer and Head of InternationalRead the original story w/Photo

    Jul 19, 2018 | The Galveston County Daily News

    Jul 19, 2018-- Trevi Therapeutics, Inc. , a late-stage biopharmaceutical company focused on developing Nalbuphine ER for chronic pruritic conditions, announced today that it has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi's senior management team and be responsible for overseeing Trevi's commercial strategy and international operations.


  10. Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain MedicationsRead the original story

    Feb 22, 2018 | Customer Interaction Solutions

    Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,895,444 providing non-invasive metered nasal spray delivery of multiple opioid blockers such as nalmefene, naltrexone, methylnaltrexone and naloxone for rescue therapy in opioid overdose, as well as opioid pain medications such as morphine, buprenorphine, and nalbuphine, among others.


  11. PDEA warns pharmacies dispensing dangerous drugsRead the original story w/Photo

    Jan 14, 2018 | Sun-Star

    PAMPANGA. PDEA Central Luzon Regional Director Joseph Ladip discusses the other role of PDEA which is to regulate the distribution of dangerous drugs to public during a recent press conference.


  12. PDEA destroys P6-B drugs in CaviteRead the original story w/Photo

    Nov 10, 2017 | Manila Bulletin

    The Philippine Drug Enforcement Agency destroyed P6 billion worth of dangerous drugs at the Integrated Waste Management Incorporated , Barangay Aguado, Trece Martirez City, Cavite yesterday. Destroyed through thermal decomposition were a total of 952.69 kilograms of assorted pieces of drug evidence composed of methamphetamine hydrochloride , or shabu, cocaine, ketamine, marijuana, benzphetamine HCl, N-benzylpiperazine, zolpidem, ephedrine, propanolol, sodium carbonate, valium, nitrazepam, nalbuphine, clonazepam, alprazolam, midazolam, methylphenidate, MDMA, codeine, pseudoephedrine, and expired medicines; and liquid shabu weighing 1,070,159 ml .


  13. Prurigo Nodularis Treatment And Management Market trends estimates high demand by 2027Read the original story w/Photo

    Nov 6, 2017 |

    Prurigo nodularis is a type of highly pruritic skin disease characterized by a symmetrical distribution of erosive, itchy, hyperkeratotic nodules and papules. The prurigo nodularis disease chronification progresses from scratching which takes the patient from papules to nodules and then to plaques formation.


  14. Trevi Therapeutics Hires Dr. Helena Brett-Smith as Chief Development OfficerRead the original story

    Oct 12, 2017 | Customer Interaction Solutions

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus , today announced that it has hired Helena Brett-Smith, M.D., as Chief Development Officer. Dr. Brett-Smith has more than 25 years of clinical and drug development experience.